Skip to main content

Abeona Therapeutics Inc. (ABEO)

NASDAQ: ABEO · IEX Real-Time Price · USD
0.650 0.016 (2.49%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap66.25M
Revenue (ttm)3.00M
Net Income (ttm)-54.08M
Shares Out101.92M
EPS (ttm)-0.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume559,100
Open0.640
Previous Close0.634
Day's Range0.620 - 0.662
52-Week Range0.560 - 3.790
Beta1.52
AnalystsStrong Buy
Price Target5.00 (+669.2%)
Earnings DateNov 15, 2021

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for th...

IndustryBiotechnology
IPO DateSep 19, 1980
CEOJoao Siffert
Employees76
Stock ExchangeNASDAQ
Ticker SymbolABEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is 5.00, which is an increase of 669.23% from the latest price.

Price Target
$5.00
(669.23% upside)
Analyst Consensus: Strong Buy

News

Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

2 weeks ago - Zacks Investment Research

Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Ed...

NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annua...

2 weeks ago - GlobeNewsWire

Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conf...

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company'...

3 weeks ago - GlobeNewsWire

Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference

NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Ex...

3 weeks ago - GlobeNewsWire

Abeona Therapeutics Reports Third Quarter Financial Results

Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening

3 weeks ago - GlobeNewsWire

Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit

NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., ...

1 month ago - GlobeNewsWire

Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously dis...

1 month ago - GlobeNewsWire

Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality

NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice...

1 month ago - GlobeNewsWire

Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Bi...

Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board

2 months ago - GlobeNewsWire

Abeona Therapeutics to Present at Upcoming Investor Conferences

NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's mana...

3 months ago - GlobeNewsWire

Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as C...

3 months ago - GlobeNewsWire

Abeona Therapeutics Reports Second Quarter Financial Results

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study

4 months ago - GlobeNewsWire

Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy

Abeona Therapeutics Inc (NASDAQ: ABEO) has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA).  ABO-102 is current...

4 months ago - Benzinga

Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilipp...

Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease

4 months ago - GlobeNewsWire

Abeona Stock Moves Higher After MPS IIIA Gene Therapy Shows Increase In Brain Volume

Abeona Therapeutics Inc (NASDAQ: ABEO) announced magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A study of ABO-102 gene therapy in Sanfilippo Syndrome Type A (MPS IIIA). Data indicat...

4 months ago - Benzinga

Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome ...

New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS...

4 months ago - GlobeNewsWire

Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystro...

NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical...

4 months ago - GlobeNewsWire

Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder

Abeona Therapeutics Inc (NASDAQ: ABEO) has announced updated data from Phase 1/2a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).  The da...

5 months ago - Benzinga

Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullos...

NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial r...

5 months ago - GlobeNewsWire

Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference

NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and...

6 months ago - GlobeNewsWire

Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out

These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?

Other symbols:LOTZOCGTYME
6 months ago - PennyStocks

Abeona Therapeutics Issues Letter to Stockholders

NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in...

6 months ago - GlobeNewsWire

Abeona Therapeutics Appoints Head of Research & Clinical Development

NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas Seshadri,...

6 months ago - GlobeNewsWire

Abeona Therapeutics Reports First Quarter Financial Results

Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study

6 months ago - GlobeNewsWire

Moving Average Crossover Alert: Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

6 months ago - Zacks Investment Research